<DOC>
	<DOCNO>NCT01192945</DOCNO>
	<brief_summary>The purpose non-interventional study collect data efficiency safety Azacitidin routine application .</brief_summary>
	<brief_title>Non-interventional Study With Azacitidin ( Vidaza® )</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients eligible haematopoietic stem cell transplantation , least 18 year old ( age limit top ) one follow disease : myelodysplastic syndrome ( MDS ) intermediate risk 2 high risk accord International Prognostic Scoring System ( IPSS ) chronic myelomonocytic leukemia ( CMML ) 1029 % marrow blast without myeloproliferative disorder acute myeloid leukemia ( AML ) 2030 % blast multilineage dysplasia accord classification World Health Organisation ( WHO ) . Contraindication accord summary product characteristic Vidaza® Signed patient inform consent form available Patients advance malignant hepatic tumor Pregnant nursing woman , men woman ( childbearing age ) unwilling apply reliable method contraception three month treatment Azacitidine Necessary plan treatment systemic cytostatics Known medical history severe decompensatoric cardiac insufficiency Medical history clinically unstable cardiac pulmonary disease Known suspect hypersensitivity azacitidine mannitol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Azacitidin</keyword>
	<keyword>Vidaza</keyword>
	<keyword>Piaza</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>CMML</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>daily routine</keyword>
	<keyword>concomitant antiemetic therapy</keyword>
	<keyword>germany</keyword>
	<keyword>non-interventional study</keyword>
</DOC>